GameStop: Consensus Estimates Point To Negative EBITDA For Q3

GameStop (NYSE: GME) will be reporting its third quarter financial results on December 8th after the market closes. Analysts have a consensus $88 12-month price target on the company, via a total of 3 analysts, with 1 analyst having a hold rating, another analyst having a sell rating, and the last analyst having a strong sell rating. The street high comes in at a $190 price target, and the lowest target sits at $24.

Only 4 analysts have revenue estimates for the third quarter. The mean revenue estimate between all 4 analysts is $1.19 billion; this number has been up and down but is flat now since early June. The highest revenue estimate is $1.30 billion, while the lowest is $1.01 billion.

Onto EBITDA estimates, there are currently only 2 analysts who have third quarter EBITDA estimates. The mean is currently -$15 million, with this number being slightly revised lower since early June. The street high estimate currently sits at $12 million in EBITDA and the lowest is -$42 million.

Analysts estimate that quarterly earnings per share will come in at -$0.52, with this number being flat since early June. Street high is -$0.04 and the lowest estimate is -$0.87 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The $30,000 Gold Case Just Got Stronger | Simon Marcotte

Why Silver’s Move Is ‘Scary’ to Some Miners | Frank Basa

Are Commodities Entering a Generational Cycle? | Terry Lynch

Recommended

CBS News Cuts Staff and Shuts Radio Network in Early Bari Weiss Era

Steadright Closes Out Financing, Raising $1.6 Million For Moroccan Strategy

Related News

Cineplex: Canaccord Lowers Target To $17 From $19

On February 11th, Cineplex Inc (TSX: CGX) reported its fourth quarter financial results. The company...

Tuesday, February 15, 2022, 05:17:00 PM

Small Pharma: Canaccord Initiates Coverage With $1.00 Price Target

Canaccord Genuity recently initiated coverage on Small Pharma Inc (TSXV: DMT), a company that is...

Sunday, June 13, 2021, 01:08:00 PM

Trulieve: Canaccord Retains $97 Price Target Following Harvest Health Transaction

On October 1, Trulieve Cannabis (CSE: TRUL) announced that they completed their $1.75 billion acquisition...

Sunday, October 10, 2021, 01:03:00 PM

Green Thumb: Despite Earnings Beat, Analysts Lower Targets On Sector Headwinds

On August 3, Green Thumb Industries (CSE: GTII) reported its second quarter financial results. The...

Saturday, August 6, 2022, 05:18:00 PM

Canaccord Estimates Alimentation Couche-Tard Reports Q1 EBITDA Of $1.3 Billion

On August 31, Alimentation Couche-Tard’s (TSX: ATD.B) will be reporting its fiscal first quarter financial...

Sunday, August 29, 2021, 11:04:00 AM